Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Abstract Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the...

Full description

Bibliographic Details
Main Authors: Francesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, Federico Itri, Caroline Besson, Julio Dávila-Valls, Sonia Martín-Pérez, Luana Fianchi, Laman Rahimli, Giuseppe Tarantini, Federica Irene Grifoni, Mariarita Sciume, Jorge Labrador, Raul Cordoba, Alberto López-García, Nicola S. Fracchiolla, Francesca Farina, Emanuele Ammatuna, Antonella Cingolani, Daniel García-Bordallo, Stefanie K. Gräfe, Yavuz M. Bilgin, Michelina Dargenio, Tomás José González-López, Anna Guidetti, Tobias Lahmer, Esperanza Lavilla-Rubira, Gustavo-Adolfo Méndez, Lucia Prezioso, Martin Schönlein, Jaap Van Doesum, Dominik Wolf, Ditte Stampe Hersby, Ferenc Magyari, Jens Van Praet, Verena Petzer, Carlo Tascini, Iker Falces-Romero, Andreas Glenthøj, Oliver A. Cornely, Livio Pagano
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Journal of Hematology & Oncology
Subjects:
COVID-19
Passive immunization
Tixagevimab/cilgavimab
Hematologic malignancies
Online Access:https://doi.org/10.1186/s13045-023-01423-7

Internet

https://doi.org/10.1186/s13045-023-01423-7

Similar Items